The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study
Open accessAbstract
Background: In the 2-year CLARITY study, cladribine tablets significantly improved clinical and magnetic resonance imaging (MRI) outcomes (vs placebo) in patients with relapsing–remitting multiple sclerosis (MS). Objective: To assess the safety and efficacy of cladribine treatment in a 2-year Extension study. Methods: In this 2-year Extension study, placebo recipients from CLARITY received cladribine 3.5 mg/kg; cladribine recipients were re-randomized 2:1 to cladribine 3.5 mg/kg or placebo, with blind maintained. Results: A total of 806 patients were assigned to treatment. Adverse event rates were generally similar between groups, but lymphopenia Grade ⩾ 3 rates were higher with cladribine than placebo (Grade 4 lymphopenia occurred infrequently). In patients receiving cladribine 3.5 mg/kg in CLARITY and experiencing lymphopenia Grade ⩾ 3 in the Extension, >90% of those treated with cladribine 3.5 mg/kg and all treated with placebo in the Extension, recovered to Grade 0–1 by study end. Cladribine treatment in CLARITY produced efficacy improvements that were maintained in patients treated with placebo in the Extension; in patients treated with cladribine 3.5 mg/kg in CLARITY, approximately 75% remained relapse-free when given placebo during the Extension. Conclusion: Cladribine tablets treatment for 2 years followed by 2 years’ placebo treatment produced durable clinical benefits similar to 4 years of cladribine treatment with a low risk of severe lymphopenia or clinical worsening. No clinical improvement in efficacy was apparent following further treatment with cladribine tablets after the initial 2-year treatment period in this trial setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Kappos, L., Radue, E.-W., O'Connor, P., Polman, C., Hohlfeld, R., Calabresi, P., Selmaj, K., Agoropoulou, C., Leyk, M., Zhang-Auberson, L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909494 · Cited by 2,644
Cohen, J. A., Coles, A. J., Arnold, D. L., Confavreux, C., Fox, E. J., Hartung, H.-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., Fisher, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61769-3 · Cited by 1,205
Self-citationA Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
Giovannoni, G., Comi, G., Cook, S., Rammohan, K., Rieckmann, P., Sørensen, P. S., Vermersch, P., Chang, P., Hamlett, A., Musch, B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0902533 · Cited by 1,023
Self-citationCladribine (2-chlorodeoxyadenosine)
Beutler, E. (1992) · The Lancet · doi:10.1016/0140-6736(92)92826-2 · Cited by 348
The treatment of chronic progressive multiple sclerosis with cladribine.
Beutler, E., Sipe, J. C., Romine, J. S., Koziol, J. A., McMillan, R., & Zyroff, J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.4.1716 · Cited by 208
Menzin, J., Caon, C., Nichols, C., White, L. A., Friedman, M., & Pill, M. W. (2013) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2013.19.s1.s24 · Cited by 204
Cook, S. D., Vermersch, P., Comi, G., Giovannoni, G., Rammohan, K. W., Rieckmann, P., Sørensen, P. S., Hamlett, A., Miret, M., Weiner, J., et al. (2011) · Multiple Sclerosis Journal · doi:10.1177/1352458510391344 · Cited by 141
Self-citationNo evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine
Pakpoor, J., Disanto, G., Altmann, D. R., Pavitt, S. H., Turner, B. P., Marta, M., Juliusson, G., Baker, D., Chataway, J., & Schmierer, K. (2015) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000158 · Cited by 137
Alstadhaug, K. B., Hallstensen, R. F., & Odeh, F. (2016) · Journal of Clinical Virology · doi:10.1016/j.jcv.2016.12.005 · Cited by 21
Cited by
Geladaris, A., Torke, S., & Weber, M. S. (2022) · CNS Drugs · doi:10.1007/s40263-022-00951-z · Cited by 45
Schiavetti, I., Signori, A., Albanese, A., Frau, J., Cocco, E., Lorefice, L., di Lemme, S., Fantozzi, R., Centonze, D., Landi, D., et al. (2026) · European Journal of Neurology · doi:10.1111/ene.70763
Metadata
- Authors
- Giovannoni, G., Soelberg Sorensen, P., Cook, S., Rammohan, K., Rieckmann, P., Comi, G., Dangond, F., Adeniji, A. K., & Vermersch, P.
- Venue
- Multiple Sclerosis Journal
- Publisher
- SAGE Publications
- Published
- 2017-09-05
- Volume
- 24
- Issue
- 12
- Pages
- 1594-1604
- ISSN
- 1352-4585 (ISSN-L)
- 1477-0970
- OpenAlex
- W2751578374
- Cited by
- 338
- References
- 9
- FWCI
- 20.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. https://app.cochat.ai/papers/10.1177/1352458517727603
- The paper
- Giovannoni, G., Soelberg Sorensen, P., Cook, S., Rammohan, K., Rieckmann, P., Comi, G., Dangond, F., Adeniji, A. K., & Vermersch, P. (2018). Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. Multiple Sclerosis Journal. https://doi.org/10.1177/1352458517727603
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.